Dapagliflozin reduced the risk of HHF in patients with T2DM. The absolute risk reduction was greater in patients with a higher baseline risk of HHF. A novel risk score was developed to identify patients with T2DM at high risk for hospitalization for heart failure (HHF). This score can be used to identify patients who may benefit most from treatment with SGLT2 inhibitors like Dapagliflozin. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.